We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ginkgo Bioworks Holdings, Inc. (DNA) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
Ginkgo Bioworks Holdings, Inc. (DNA - Free Report) ended the recent trading session at $15.12, demonstrating a -4.49% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.63%. Meanwhile, the Dow experienced a drop of 0.65%, and the technology-dominated Nasdaq saw a decrease of 0.47%.
Prior to today's trading, shares of the company had gained 43% outpaced the Medical sector's gain of 3.09% and the S&P 500's gain of 0.92%.
The investment community will be closely monitoring the performance of Ginkgo Bioworks Holdings, Inc. in its forthcoming earnings report. In that report, analysts expect Ginkgo Bioworks Holdings, Inc. to post earnings of -$1.24 per share. This would mark a year-over-year decline of 14.81%. Meanwhile, the latest consensus estimate predicts the revenue to be $39 million, indicating a 56.2% decrease compared to the same quarter of the previous year.
DNA's full-year Zacks Consensus Estimates are calling for earnings of -$5.27 per share and revenue of $181 million. These results would represent year-over-year changes of +49.13% and -20.28%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Ginkgo Bioworks Holdings, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Ginkgo Bioworks Holdings, Inc. is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 84, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ginkgo Bioworks Holdings, Inc. (DNA) Dips More Than Broader Market: What You Should Know
Ginkgo Bioworks Holdings, Inc. (DNA - Free Report) ended the recent trading session at $15.12, demonstrating a -4.49% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.63%. Meanwhile, the Dow experienced a drop of 0.65%, and the technology-dominated Nasdaq saw a decrease of 0.47%.
Prior to today's trading, shares of the company had gained 43% outpaced the Medical sector's gain of 3.09% and the S&P 500's gain of 0.92%.
The investment community will be closely monitoring the performance of Ginkgo Bioworks Holdings, Inc. in its forthcoming earnings report. In that report, analysts expect Ginkgo Bioworks Holdings, Inc. to post earnings of -$1.24 per share. This would mark a year-over-year decline of 14.81%. Meanwhile, the latest consensus estimate predicts the revenue to be $39 million, indicating a 56.2% decrease compared to the same quarter of the previous year.
DNA's full-year Zacks Consensus Estimates are calling for earnings of -$5.27 per share and revenue of $181 million. These results would represent year-over-year changes of +49.13% and -20.28%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Ginkgo Bioworks Holdings, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Ginkgo Bioworks Holdings, Inc. is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 84, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.